Bococizumab is a remarkable anti-PCSK9 antibody effectively developed to address hypercholesterolemia. It therapeutic agent interacts with the PCSK9 protein, a key regulator of cholesterol amounts. By inhibiting the https://www.targetmol.com/compound/bococizumab